Patents Examined by Gary B. Nickol
-
Patent number: 11491197Abstract: A composition for treating or preventing COVID-19 infection is described. The composition includes attenuated Measles virus particles; attenuated Mumps virus particles; attenuated Rubella II virus particles; scorpion antivenom; and a pharmaceutically acceptable carrier. The composition can be used in a method of treating COVID-19 infection in a subject, and can also be used in a method of vaccinating a subject to decrease the risk or severity of infection by COVID-19.Type: GrantFiled: October 8, 2021Date of Patent: November 8, 2022Inventor: Heba Hamida
-
Patent number: 11485961Abstract: Polypeptides, and methods for their use, are disclosed that have an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:1, are provided, wherein (a) the polypeptide degrades a PFQFQLPY (SEQ ID NO: 140) peptide and/or a PFPQPQQPF (SEQ ID NO: 68) at pH 4; (b) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp; and (c) the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174, and 456.Type: GrantFiled: September 14, 2020Date of Patent: November 1, 2022Assignees: University of Washington, The Regents of the University of CaliforniaInventors: Ingrid Swanson Pultz, Clancey Wolf, Justin Bloomfield Siegel, Christine Elaine Tinberg, Lance Stewart, David Baker
-
Patent number: 11485973Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.Type: GrantFiled: September 23, 2020Date of Patent: November 1, 2022Assignee: SNIPR Biome ApSInventors: Morten Sommer, Virginia Martinez, Eric Van der Helm, Jakob Krause Haaber, Ana De Santiago Torio, Christian Grøndahl, Jasper Clube
-
Patent number: 11484585Abstract: Provided herein are genetically engineered Vibrio cholerae bacterial strains, compositions including the bacterial strains, and methods of using the same for the prevention of Vibrio cholerae infection in a subject.Type: GrantFiled: July 12, 2018Date of Patent: November 1, 2022Assignee: The Brigham and Women's Hospital, Inc.Inventors: Matthew K. Waldor, Troy Hubbard, Gabriel Billings
-
Patent number: 11479609Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.Type: GrantFiled: February 2, 2022Date of Patent: October 25, 2022Assignee: Alpine Immune Sciences, Inc.Inventors: Ryan Swanson, Michael Kornacker
-
Patent number: 11471708Abstract: This invention provides novel injectable compositions comprising botulinum toxin that may be administered to a subject for various therapeutic, aesthetic and/or cosmetic purposes. The injectable compositions contemplated by the invention exhibit one or more advantages over conventional botulinum toxin formulations, including reduced antigenicity, a reduced tendency to undergo unwanted localized diffusion following injection, increased duration of clinical efficacy or enhanced potency relative, faster onset of clinical efficacy, and/or improved stability.Type: GrantFiled: October 17, 2019Date of Patent: October 18, 2022Assignee: Revance Therapeutics, Inc.Inventors: Curtis L. Ruegg, Hongran Fan Stone, Jacob M. Waugh
-
Patent number: 11471531Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.Type: GrantFiled: December 23, 2020Date of Patent: October 18, 2022Assignee: SNIPR Technologies LimitedInventors: Jasper Clube, Morten Sommer, Christian Grøndahl
-
Patent number: 11471530Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.Type: GrantFiled: April 19, 2019Date of Patent: October 18, 2022Assignee: SNIPR Technologies LimitedInventor: Jasper Clube
-
Patent number: 11464841Abstract: Disclosed herein are compositions comprising optimized consensus TERT antigens and methods for treating cancer and in particular immunogenic compositions that treat and provide protection against tumor.Type: GrantFiled: September 29, 2017Date of Patent: October 11, 2022Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.Inventors: David Weiner, Jian Yan
-
Patent number: 11464813Abstract: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.Type: GrantFiled: April 6, 2021Date of Patent: October 11, 2022Assignee: University of Maryland, BaltimoreInventors: Jacques Ravel, Michael France, Lindsay Rutt, Bing Ma
-
Patent number: 11464843Abstract: Antigenic molecules and compositions described herein protect against infection by typhoidal and non-typhoidal Salmonella serovars. Methods of immunization comprise the use of the antigenic molecules.Type: GrantFiled: January 27, 2020Date of Patent: October 11, 2022Assignees: The Board of Regents for Oklahoma State University, University of KansasInventors: Wendy L. Picking, William D. Picking
-
Patent number: 11459400Abstract: Aspects of the disclosure relate to compositions of enzyme-binding polypeptides (EBPs) that modify the substrate specificity of an enzyme and a method for identifying an EBP that modifies substrate specificity of an enzyme binding at least one substrate, the method comprising: contacting the enzyme with a polypeptide library comprising a plurality of EBPs that bind different epitopes of the enzyme; identifying EBPs that bind to the enzyme to form an EBP-enzyme complex; assaying for the activity level and substrate specificity of the EBP-enzyme complex; and identifying EBPs that modify the substrate specificity of the enzyme by identifying EBPs that, when in an EBP-enzyme complex, have a different substrate specificity than un-complexed EBP; wherein the catalytic rate constant of the EBP-enzyme complex is ?50% of the un-complexed enzyme for at least one substrate and/or wherein the EBP-enzyme complex retains binding to a substrate.Type: GrantFiled: July 15, 2016Date of Patent: October 4, 2022Assignee: The University of ChicagoInventors: Shohei Koide, Shun-Ichi Tanaka, Akiko Koide
-
Patent number: 11447541Abstract: Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.Type: GrantFiled: June 22, 2021Date of Patent: September 20, 2022Assignees: AbCellera Biologies Inc., The United States of America, as represented by the Secretary, Department of Health and Human Svcs.Inventors: Kathryn Westendorf, Stefanie Zentelis, Krithika Muthuraman, Kevin Jepson, Ester Falconer, John Mascola, Barney Graham, Kizzmekia Corbett, Julie Ledgerwood, Lingshu Wang, Olubukola Abiona, Wei Shi, Wing-pui Kong, Yi Zhang, Bryan Edward Jones, Denisa Foster, Julian Davies, Qing Chai, Christopher Carl Frye, Ganapathy Gopalrathnam, Jörg Hendle, John Michael Sauder, Jeffrey Streetman Boyles, Anna Pustilnik
-
Patent number: 11447542Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O2 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae) and/or protects mice from a lethal Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.Type: GrantFiled: August 4, 2017Date of Patent: September 20, 2022Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SAInventors: Qun Wang, Charles K. Stover, Meghan Pennini, Xiaodong Xiao, Davide Corti, Elisabetta Cameroni, Martina Beltramello, Gilad Kaplan, Anna DeMarco
-
Patent number: 11440951Abstract: Provided here are immunoglobulins and compositions containing one or more of said immunoglobulins reactive to a strain of Marburg virus. The immunoglobulins and compositions comprising said immunoglobulins can be used prophylactically to prevent a Marburg virus infection or to treat a patient that has been exposed to a Marburg virus in order to reduce a symptom.Type: GrantFiled: March 9, 2018Date of Patent: September 13, 2022Assignee: THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMYInventors: Philippe Thullier, Jeffrey Froude, II, John Dye, Jr.
-
Patent number: 11426455Abstract: The invention provides an immunogenic composition comprising staphylococcal antigens, containing protein antigens and conjugates of capsular polysaccharides, n particular Hla, ClfA, SpA and conjugates of capsular polysaccharides. Adjuvanted formulations are also provided. The invention may find use in the prevention and treatment of staphylococcal infections, in particular S. aureus infection and disease.Type: GrantFiled: February 12, 2019Date of Patent: August 30, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Fabio Bagnoli, Carine Goraj
-
Patent number: 11426454Abstract: The present invention relates to the field of tuberculosis vaccines, and specifically relates to a tuberculosis vaccine, a preparation method thereof, and a use thereof. To address the problem of existing vaccines being unsuitable for patients having weak immunity, the present invention provides a preparation method for a tuberculosis vaccine: first obtaining Mycobacterium single cell bacteria, and using low dosage radiation to irradiate periodically the Mycobacterium single cell bacteria, so as to obtain the tuberculosis vaccine. The present invention completely retains all of the antigen characteristics of the bacteria, and can more rapidly stimulate stronger specific immune responses, thereby achieving effective and long-lasting immunity. The vaccine prepared using the present invention has low toxicity, is rapid-acting and safer, and can be used for the prevention and treatment of tuberculosis for people having immunodeficiency.Type: GrantFiled: July 1, 2019Date of Patent: August 30, 2022Assignee: Sichuan UniversityInventors: Zhenling Wang, Yuquan Wei
-
Patent number: 11421227Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.Type: GrantFiled: March 11, 2021Date of Patent: August 23, 2022Assignee: SNIPR Biome ApSInventors: Morten Sommer, Virginia Martinez, Eric Van Der Helm, Jakob Krause Haaber, Ana De Santiago Torio, Christian Grøndahl, Jasper Clube
-
Patent number: 11421009Abstract: The present invention relates to a fusion protein in which transferrin is peptide-bonded to a terminal of a granulocyte-colony stimulating factor (G-CSF) protein or a G-CSF mutant protein in which the 116th threonine is substituted with cysteine in the amino acid sequence of the G-CSF. Specifically, the granulocyte-colony stimulating factor (G-CSF) mutant protein of the present invention or the transferrin fusion protein thereof displays a significantly increased specific activity and blood stability, compared with the conventional human G-CSF, and has a higher purification efficiency than the conventional PEGylated G-CSF characterized by the extended half-life, so that it can be advantageously used for preventing or treating ischemic diseases or neutropenia.Type: GrantFiled: September 19, 2019Date of Patent: August 23, 2022Assignee: PANACEA INC.Inventors: Jeong-Hyeok Yoon, Byung-Ha Chang, Bong-Seok Jin, Ji Young Bae, Soon Nam Kim, Kyeong Su Park, Yeong kyu Park, Hanjo Kim, Youngju Seo, Wooseong Jeong, KyungTae Kang
-
Patent number: 11406695Abstract: The present invention relates to methods for the recombinant expression of chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of chlamydia infection and/or the effects thereof.Type: GrantFiled: June 8, 2020Date of Patent: August 9, 2022Assignee: Merck Sharp & Dohme LLCInventors: Lan Zhang, Zhiyun Wen, Craig T. Przysiecki, Ping Qiu